The present study seeks to identify the nutritional risk factors involved in the development of neuropathies induced by chemotherapeutic treatments. Unlike the gastrointestinal or hematological adverse effects of chemotherapy there is no protective treatment strategy for polyneuropathy. The aim of this study was to find possible deficiencies in nutritional factors, which can be used for supplementation in the future for prevention of chemotherapy-induced neuropathy development. We analyzed 70 patients undergoing paclitaxel chemotherapy and evaluated the risk factors involved in chemotherapy-induced peripheral neuropathy (CIPN). Several risk factors were considered in the development of CIPN, including deficiency of vitamin B1, B6, and D and fatty acids. The occurrence of CIPN complication in 60% cases was observed. We found significant differences in vitamin D and saturated fatty acid concentration. Vitamin D levels in the group without CIPN were estimated to be 38.2 (24.95, 47.63) nmol/L, whereas in the group with CIPN it was determined to be 25.6 (19.7, 32.55) nmol/L, p = 0.008. The level of total saturated fatty acids in the group without CIPN was of 32.613 Area % (31.322; 36.262), whereas in the group with CIPN it was of 34.209 Area % (32.86; 39.386), p = 0.01. The obtained results suggest a diet lower in saturated fatty acid content during chemotherapy. The most significant finding was that supplementation of vitamin D before chemotherapy could be an efficient neuroprotective in CIPN prophylaxis, as significantly lower levels 25OH derivative of vitamin D were observed in the CIPN group throughout the study period.

Department of Neurology University Hospital Hradec Kralove 50005 Hradec Kralove Czech

Department of Oncology and Radiotherapy University Hospital Hradec Kralove 50005 Hradec Kralove Czech

Department of Research and Development University Hospital Hradec Kralove 50005 Hradec Kralove Czech

Institute of Clinical Biochemistry and Diagnostics University Hospital Hradec Kralove 50005 Hradec Kralove Czech

Zobrazit více v PubMed

Cancernetwork. [(accessed on 5 April 2017)]; Available online: http://www.cancernetwork.com/oncology-nursing/chemotherapy-induced-peripheral-neuropathy-cancer-survivors.

Cancer Supportive Survivorship Care. [(accessed on 5 April 2017)]; Available online: http://www.cancersupportivecare.com/nervepain.html.

Chau Y.P., Chien C.L., Lu K.S. The permeability of capillaries among the small granule-containing cells in rat superior cervical ganglia: And ultrastructural lanthanum tracer study. Histol. Histopathol. 1991;6:261–268. PubMed

Chaudhry V., Rowinsky E.K., Sartorius S.E., Donehower R.C., Cornblath D.R. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies. Ann. Neurol. 1994;35:304–311. doi: 10.1002/ana.410350310. PubMed DOI

Forsyth P.A., Balmaceda C., Peterson K., Seidman A.D., Brasher P., DeAngelis L.M. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J. Neuro Oncol. 1997;35:47–53. doi: 10.1023/A:1005805907311. PubMed DOI

Wampler M.A., Hamolsky D., Hamel K., Melisko M., Topp K.S. Case report: Painful peripheral neuropathy following treatment with docetaxel for breast cancer. Clin. J. Oncol. Nurs. 2005;9:189–193. doi: 10.1188/05.CJON.189-193. PubMed DOI

Up To Date. [(accessed on 5 April 2017)]; Available online: http://www.uptodate.com/contents/image?imageKey=ONC%2F67516&topicKey=ONC%2F2836&source=see_link&utdPopup=true.

Watkins S.M., Griffin J.P. High incidence of vincristine-induced neuropathy in lymphomas. Br. Med. J. 1978;11:610–612. doi: 10.1136/bmj.1.6113.610. PubMed DOI PMC

Van der Hoop R.G., van der Burg M.E., ten Bokkel Huinink W.W., van Houwelingen C. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer. 1990;66:1697–1702. doi: 10.1002/1097-0142(19901015)66:8<1697::AID-CNCR2820660808>3.0.CO;2-G. PubMed DOI

Amptoulach S., Tsavaris N. Neurotoxicity caused by the treatment with platinum analogues. Chemother. Res. Pract. 2011 doi: 10.1155/2011/843019. PubMed DOI PMC

Chaudhry V., Chaudhry M., Crawford T.O., Simmons-O’Brien E., Griffin J.W. Toxic neuropathy in patients with pre-existing neuropathy. Neurology. 2003;60:337–340. doi: 10.1212/01.WNL.0000043691.53710.53. PubMed DOI

Cavaletti G., Bogliun G., Marzorati L., Zincone A., Piatti M., Colombo N., Franchi D., La Presa M.T., Lissoni A., Buda A., et al. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann. Oncol. 2004;15:1439–1442. doi: 10.1093/annonc/mdh348. PubMed DOI

Ghoreishi Z., Esfahani A., Djazayeri A., Djalali M., Golestan B., Ayromlou H., Hashemzade S., Asghari Jafarabadi M., Montazeri V., Keshavarz S.A., et al. Omega-3 fatty acids are protective against paclitaxel-induces peripheral neuropathy: A randomized double-blind placebo controlled trial. BMC Cancer. 2012;12:355. doi: 10.1186/1471-2407-12-355. PubMed DOI PMC

Schloss J.M., Colosimo M., Airey C., Masci P., Linnane A.W., Vitetta L. A randomized, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing development of chemotherapy-induced peripheral neuropathy (CIPN) Support. Care Cancer. 2017;25:195–204. doi: 10.1007/s00520-016-3404-y. PubMed DOI

Chabas J.F., Alluin O., Rao G., Garcia S., Lavaut M.N., Risso J.J., Legre R., Magalon G., Khrestchatisky M., Marqueste T., et al. Vitamin D2 potentiates axon regeneration. J. Neurotrauma. 2008;25:1247–1256. doi: 10.1089/neu.2008.0593. PubMed DOI

Hahn A., Schlotter C.M., Rossmanith W.G., Ulmer H., Staiger H., Villena C. Neoadjuvant chemotherapy for breast cancer with weekly nab-paclitaxel by epirubicin and cyclofosfamide-results of a case series. In Vivo. 2014;28:235–241. PubMed

Michigan Neuropathy Screening Instrument. [(accessed on 5 April 2017)]; Available online: http://www.med.umich.edu/borc/profs/documents/svi/MNSI_patient.pdf.

Cavaletti G., Bogliun G., Marzogatti L., Zincone A., Marzola M., Colombo N., Tredici G. Peripheral toxicity of taxol in patients previously treated with cisplatin. Cancer. 1995;75:1141–1150. doi: 10.1002/1097-0142(19950301)75:5<1141::AID-CNCR2820750514>3.0.CO;2-U. PubMed DOI

Schloss J., Colosimo M., Vitetta L. New insights into potential prevention and management options for chemotherapy-induced peripheral neuropathy. Asia Pac. J. Oncol. Nurs. 2016;3:73–85. doi: 10.4103/2347-5625.170977. PubMed DOI PMC

Rowinsky E.K., Eisenhauer E.A., Chaundry V., Arbuck S.G., Donehower R.C. Clinical toxicities encountered with paclitaxel (TAXOL) Semin. Oncol. 1993;4:1–15. PubMed

Powe C.E., Ricciardi C., Berg A.H., Erdenesanaa D., Collerone G., Ankers E., Wenger J., Karumanchi S.A., Thadhani R., Bhan I. Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J. Bone Miner. Res. 2011;26:1609–1616. doi: 10.1002/jbmr.387. PubMed DOI PMC

Watson R.R., De Meester F. Omega-3 Fatty Acids in Brain and Neurological Health. 1st ed. Elsevier; Waltham, MA, USA: 2014. p. 496.